Cargando…

Bevacizumab for the Treatment of Glioblastoma

Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Gil, Miguel J., Mesia, Carlos, Rey, Montserrat, Bruna, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/
https://www.ncbi.nlm.nih.gov/pubmed/23843722
http://dx.doi.org/10.4137/CMO.S8503
_version_ 1782273400633294848
author Gil-Gil, Miguel J.
Mesia, Carlos
Rey, Montserrat
Bruna, Jordi
author_facet Gil-Gil, Miguel J.
Mesia, Carlos
Rey, Montserrat
Bruna, Jordi
author_sort Gil-Gil, Miguel J.
collection PubMed
description Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy.
format Online
Article
Text
id pubmed-3682734
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36827342013-07-10 Bevacizumab for the Treatment of Glioblastoma Gil-Gil, Miguel J. Mesia, Carlos Rey, Montserrat Bruna, Jordi Clin Med Insights Oncol Review Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy. Libertas Academica 2013-06-06 /pmc/articles/PMC3682734/ /pubmed/23843722 http://dx.doi.org/10.4137/CMO.S8503 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
spellingShingle Review
Gil-Gil, Miguel J.
Mesia, Carlos
Rey, Montserrat
Bruna, Jordi
Bevacizumab for the Treatment of Glioblastoma
title Bevacizumab for the Treatment of Glioblastoma
title_full Bevacizumab for the Treatment of Glioblastoma
title_fullStr Bevacizumab for the Treatment of Glioblastoma
title_full_unstemmed Bevacizumab for the Treatment of Glioblastoma
title_short Bevacizumab for the Treatment of Glioblastoma
title_sort bevacizumab for the treatment of glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682734/
https://www.ncbi.nlm.nih.gov/pubmed/23843722
http://dx.doi.org/10.4137/CMO.S8503
work_keys_str_mv AT gilgilmiguelj bevacizumabforthetreatmentofglioblastoma
AT mesiacarlos bevacizumabforthetreatmentofglioblastoma
AT reymontserrat bevacizumabforthetreatmentofglioblastoma
AT brunajordi bevacizumabforthetreatmentofglioblastoma